HighTide TherapeuticsHTTIF 14 PB Ratio is 4.07 as of Jun. 25, 2026. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, HighTide Therapeutics ranks worse than 65.86% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HighTide Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HighTide Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where HighTide Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HighTide Therapeutics (HTTIF) has a PB Ratio of 4.07 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HighTide Therapeutics and its competitors. According to the industry distribution chart, HighTide Therapeutics ranks #812 out of 1233 companies in the Biotechnology industry, placing it in the top 65.9%.
Is HighTide Therapeutics' PB Ratio too high?
HighTide Therapeutics' current PB Ratio is 4.07. The Biotechnology industry median PB Ratio is 2.80. HighTide Therapeutics' value of 4.07 is 45.4% above this industry median. Based on the distribution chart, HighTide Therapeutics ranks #812 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #812 out of 1233 companies for PB Ratio. This places HighTide Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. HighTide Therapeutics' value of 4.07 is 45.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HighTide Therapeutics's current PB Ratio of 4.07 is 45.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HighTide Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current PB Ratio is 4.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current PB Ratio of 4.07. The current PB Ratio is 4.07 and 45.4% above the Biotechnology industry median of 2.80. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current PB Ratio is 4.07 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score
Get the complete analysis for HTTIF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTTIF has been successfully added to your 
